CN113736787A - 靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 - Google Patents
靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 Download PDFInfo
- Publication number
- CN113736787A CN113736787A CN202111106595.5A CN202111106595A CN113736787A CN 113736787 A CN113736787 A CN 113736787A CN 202111106595 A CN202111106595 A CN 202111106595A CN 113736787 A CN113736787 A CN 113736787A
- Authority
- CN
- China
- Prior art keywords
- mouse
- gene
- atp7b
- seq
- grnas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020005004 Guide RNA Proteins 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 29
- 101100436486 Mus musculus Atp7b gene Proteins 0.000 title claims abstract description 24
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 title claims abstract description 22
- 208000018839 Wilson disease Diseases 0.000 title claims abstract description 21
- 238000010172 mouse model Methods 0.000 title claims abstract description 19
- 102000012437 Copper-Transporting ATPases Human genes 0.000 title claims abstract description 16
- 101150075644 ATP7B gene Proteins 0.000 claims abstract description 26
- 230000008685 targeting Effects 0.000 claims abstract description 22
- 101150038500 cas9 gene Proteins 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 17
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 238000003209 gene knockout Methods 0.000 claims description 6
- 235000013601 eggs Nutrition 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 108700024394 Exon Proteins 0.000 claims description 3
- 210000003855 cell nucleus Anatomy 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 241000581650 Ivesia Species 0.000 claims description 2
- 238000012408 PCR amplification Methods 0.000 claims description 2
- 210000002459 blastocyst Anatomy 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 210000004940 nucleus Anatomy 0.000 claims description 2
- 101100004232 Mus musculus Bbs5 gene Proteins 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 14
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 238000011813 knockout mouse model Methods 0.000 abstract description 8
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 6
- 230000008506 pathogenesis Effects 0.000 abstract description 5
- 108091026890 Coding region Proteins 0.000 abstract description 4
- 231100000221 frame shift mutation induction Toxicity 0.000 abstract description 3
- 230000037433 frameshift Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 229910001431 copper ion Inorganic materials 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 2
- 102100031577 High affinity copper uptake protein 1 Human genes 0.000 description 2
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 101150075065 Atox1 gene Proteins 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000020856 Copper Transport Proteins Human genes 0.000 description 1
- 108091004554 Copper Transport Proteins Proteins 0.000 description 1
- 108010003232 Copper Transporter 1 Proteins 0.000 description 1
- 208000029011 Copper metabolism disease Diseases 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 101710196315 High affinity copper uptake protein 1 Proteins 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 102100034769 Thioredoxin-dependent peroxide reductase, mitochondrial Human genes 0.000 description 1
- 101710150060 Thioredoxin-dependent peroxide reductase, mitochondrial Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 101150080042 bbs5 gene Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000013173 literature analysis Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
- C12Y306/03004—Cu2+-exporting ATPase (3.6.3.4)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属分子生物学领域,具体公开了一组靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法;本发明设计了特异性靶向Atp7b基因的三条gRNA,利用cas9蛋白将Atp7b基因的Exon2‑Exon20敲除,所敲区域序列为非3倍数,造成移码突变,且敲除区域包含该基因编码区的91.91%,从而达到将该基因敲除的目的;使用CRISPR/Cas9***构建Atp7b基因敲除小鼠模型方法简单易行,周期短,拿到阳性小鼠的概率高,利用该小鼠模型可以充分研究该疾病的致病机理,并为进一步开发针对该疾病的治疗方式提供服务。
Description
技术领域
本发明属分子生物学领域,具体公开了一组靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法。
背景技术
威尔逊病(Wilson’s disease,WD)又称肝豆状核变性,是罕见的常染色体隐形遗传铜代谢疾病,本病属于风湿性疾病当中的混合性***病,临床上以肝病、神经症状为主要特征。组织中铜的蓄积增加是引起肝病、神经学病变、角膜周围出现棕绿色环(凯-弗环)、肾和其他器官发病的主要原因,且组织损伤可引起肝硬化脑基底节双侧软化、变性。据美国国家糖尿病、消化和肾病疾病研究所估计,全球约1/10000~1/30000的人患有该疾病,我国目前尚缺乏大样本多中心的威尔逊WD疾病发病率调查,但有文献分析该病在中国的发病率比西方国家高。
WD的发病机制在于ATP7B基因变异,ATP7B基因是位于细胞高尔基体膜上的铜转运ATP酶,主要在肝细胞上表达,正常人体中约90%铜离子由ATP7B介导经胆汁排出。正常情况下通过饮食摄入的铜经过肠道上皮细胞吸收后通过门静脉血转运到肝细胞的肝窦面,经过铜转运体1(CTR1)转运至肝细胞,在肝细胞内,铜离子与多个分子伴侣结合并转运到相应蛋白上发挥作用,铜离子可经抗氧化蛋白1(Atox1)转运,将其转运到高尔基体上的ATP7B分子,而后与铜蓝蛋白结合进而分泌道血液中发挥作用。当ATP7B基因发生变异导致ATP7B功能受到不同程度的损伤,铜蓝蛋白结合转运铜离子的能力也会不同程度的下降或完全消失。铜离子不能有效经过胆汁排泌导致其在肝细胞内蓄积,通过氧化应激损伤等方式损伤线粒体等细胞器,进而引起肝细胞脂肪变性、坏死与凋亡。肝细胞破坏后游离铜离子会释放到血液中引起机体其他损伤。为了研究该疾病的发病机制以及开发有效的治疗方法,构建该疾病的实验模型对于疾病的研究不可或缺,小鼠模型是目前公认到的制备人类疾病模型及研究基因组功能最有效的疾病模型,但是目前还缺乏高效的构建Wilson疾病小鼠模型的方法。
发明内容
针对现有技术不足,本发明利用CRISPR/Cas9技术快速在小鼠体内将Atp7b 基因敲除,构建WD疾病模型。CRISPR/Cas9是一种由gRNA指导,利用Cas9核酸酶对靶向基因进行编辑的技术,其工作原理是crRNA(CRISPR-derived RNA) 通过碱基配对与tracrRNA(trans-activating RNA)结合形成tracrRNA/crRNA 复合物,此复合物会引导Cas9蛋白在与crRNA配对的序列靶位点剪切双链DNA,通过人工设计crRNA和tracrRNA两种RNA,改造成具有引导作用的gRNA,从而引导Cas9蛋白对DNA的定点切割,并产生一个平末端的双链DNA缺口,进而启动DNA损伤修复机制,主要通过非同源末端连接(Non-homologous endjoining, NHEJ)或同源重组(Homologous recombination,HR)的方式将断裂上下游两端的序列连接起来。Cas9蛋白若要发挥作用需要靶位点下游的一个5’-NGG-3’基序,即PAM序列,基因特异的gRNA模板序列为位于PAM序列前,同时gRNA序列避免4个以上的T结尾,GC含量最佳为30%~70%。另外在选择gRNA时应考虑到其脱靶效应,全基因的脱靶效应需考虑脱靶位点的碱基错配数尽量不超过5个,基于多方面考虑,我们共设计了三条针对Atp7b基因的gRNA,分别靶向Exon2 的5’端和Exon20的3’端。
本发明包括以下技术方案:
一组靶向小鼠Atp7b基因的gRNA,包括三条gRNA,其核酸序列分别为:
gRNA1=SEQ ID NO 1=5’-GGCACCCAGGCCAAATGTAGGGG-3’;
gRNA2=SEQ ID NO 2=5’-GACTCTTACCACTGCTAAGTGGG-3’;
gRNA3=SEQ ID NO 3=5’-TCTTTGCTAAGGAGTAAAACTGG-3’。
进一步,一种靶向小鼠Atp7b基因的基因敲除试剂盒,所述试剂盒中包括上述一组靶向小鼠Atp7b基因的gRNA。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法,所述方法包括利用gRNA1、gRNA2、gRNA3将小鼠Atp7b基因敲除。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法,所述gRNA1靶向切割小鼠Atp7b基因Exon2的5’端,gRNA2 和gRNA3靶向切割Exon20的3’端。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法,所述gRNA1、gRNA2、gRNA3将Atp7b基因第2~第20个外显子之间的33183bp的DNA切除。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法,包括以下步骤:
1)将Cas9 mRNA以及针对Atp7b基因合成的3条gRNA混合后注射到培养于M2培养基中具有双核清晰的受精卵的细胞核中;
2)注射后的受精卵培养在特定的培养基中,培养至3.5天后每15-20个囊胚移植到假孕母鼠体内,产出小鼠,即为F0小鼠;
3)仔鼠出生后5天即可剪鼠尾提取DNA进行PCR扩增鉴定并送测序,若有检测结果为阳性则表示小鼠基因敲除成功。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法,所述步骤3中的测序引物为:
PCR测序引物=SEQ ID NO 4=5’-GTGGAAGAGAGGAGATGGTAAAC-3’。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法,所述步骤3中PCR鉴定中的引物包括:
PCR Primers1,其序列分别为:
F1=SEQ ID NO 5=5’-GTGGAAGAGAGGAGATGGTAAAC-3’;
R1=SEQ ID NO 6=5’-CATGGTTCAAGTTCACATAGTCCAG-3’。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法,所述步骤3中PCR鉴定中的引物包括:
PCR Primers2,其序列分别为:
F2=SEQ ID NO 7=5’-TCAGCTCAAGTGGTAAGTCCTGG-3’;
R1=SEQ ID NO 6=5’-CATGGTTCAAGTTCACATAGTCCAG-3’。
进一步的,使用上述一组靶向小鼠Atp7b基因的gRNA构建Wilson疾病小鼠模型的方法获得的Wilson疾病模型小鼠。
本发明具有以下有益效果:
本发明设计了特异性靶向Atp7b基因的三条gRNA,利用cas9蛋白将 Atp7b基因的Exon2-Exon20敲除,所敲区域序列为非3倍数,造成移码突变,且敲除区域包含该基因编码区的91.91%,从而达到将该基因敲除的目的。使用 CRISPR/Cas9***构建Atp7b基因敲除小鼠模型方法简单易行,周期短,拿到阳性小鼠的概率高,利用该小鼠模型可以充分研究该疾病的致病机理,并为进一步开发针对该疾病的治疗方式提供服务。
附图说明
附图1.Atp7b基因敲除小鼠的构建方案示意图;图中,深色线段表示敲除区域,实心矩形数字代表BBS5基因的外显子,gRNA region代表gRNA的剪切区域;
附图2.Atp7b基因敲除小鼠的鉴定策略;显示了用于鉴定小鼠的PCR引物的结合位点:F1、F2、R1;
附图3.Atp7b基因敲除小鼠的鉴定结果;利用PCR引物PCR Primers1进行 PCR筛选,基因敲除后的扩增产物:490bp;野生型的扩增产物:34335bp。左图为DNA分子量标记,右图为PCR的鉴定产物图;
附图4.Atp7b基因敲除小鼠的基因组测序结果,箭头指示处Atp7b基因被删除33834bp以及11bp。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。本发明中所述的适量,为本领域内普通技术人员根据国家技术规范和生产实际情况所决定的用量。本发明中所述的原料如无特殊说明,均为商业购得。
实施例
1.敲除方案设计
根据需求,查找Atp7b基因详细信息,选择基因敲除的区域尽可能包括基因的功能域部分,根据实际情况选择敲除区域,我们选择Atp7b基因敲除区域 Exon2-Exon20共33183bp序列,包含Atp7b基因整个编码区的91.91%,如附图 1所示。
2.gRNA序列设计
根据小鼠Atp7b基因的序列,设计并合成了3条针对该基因的gRNA序列,序列信息如下:
gRNA1=SEQ ID NO 1=5’-GGCACCCAGGCCAAATGTAGGGG-3’;
gRNA2=SEQ ID NO 2=5’-GACTCTTACCACTGCTAAGTGGG-3’;
gRNA3=SEQ ID NO 3=5’-TCTTTGCTAAGGAGTAAAACTGG-3’。
3.Cas9/sgRNA的显微注射
选取4~6周龄SPF级雌性小鼠作为卵子供体,小鼠腹腔注射PMSG(孕马血清促性腺素),48h后注射hCG(人血绒膜促性腺素),随即与生殖能力正常的种公鼠进行交配,采集小鼠受精卵,消化洗涤之后置于37℃培养箱中待用。将 Cas9 mRNA与实验2中人工合成的gRNA混匀后通过显微注射至小鼠受精***核中,然后移植到***母鼠输卵管壶腹部中,***鼠每隔一周进行体重称量,初步判断是否怀孕,手术后19~21天仔鼠分娩,待仔鼠5天后剪尾编号并进行PCR 检测。
4.Atp7b基因敲除小鼠的PCR鉴定
根据Atp7b基因敲除区域,我们分别在Exon2的5’端以及Exon20的3’端设计一对引物F1和R1(F1=SEQ ID NO 5=5’-GTGGAAGAGAGGAGATGGTAAAC-3’ R1=SEQ ID NO 6=5’-CATGGTTCAAGTTCACATAGTCCAG-3’),我们对出生的F0 小鼠进行PCR引物扩增并送测序,该引物在基因敲除小鼠中扩增的产物为490bp,在野生型小鼠中不能扩增出产物,鉴定结果及测序结果如附图3和4所示。将鉴定正确的阳性小鼠与野生型小鼠交配获得F1小鼠,小鼠出生14天后进行PCR 扩增鉴定小鼠纯杂合,鉴定引物如附图2所示,纯合小鼠扩增产物为490bp,杂合小鼠扩增产物为490bp/502bp,野生型小鼠扩增产物为502bp。PCR测序引物=SEQ IDNO 4=5’-GTGGAAGAGAGGAGATGGTAAAC-3’。
小鼠PCR鉴定部位为鼠尾,对于鼠尾鉴定选择粗裂解的方法提取DNA。
PCR反应体系如下:
组分 | 体积 |
ddH<sub>2</sub>O | 9.0uL |
F1(10um) | 1.0uL |
R1(10um) | 1.0uL |
Premix Taq | 12.5uL |
DNA | 1.5uL |
总共 | 25uL |
PCR反应程序如下:
将PCR产物进行琼脂糖凝胶电泳,电泳结果如附图3所示。
根据上述实验结果可知:本发明设计了特异性靶向Atp7b基因的三条gRNA,利用cas9蛋白将Atp7b基因的Exon2-Exon20敲除,所敲区域序列为非3倍数,造成移码突变,且敲除区域包含该基因编码区的91.91%,从而达到将该基因敲除的目的。使用CRISPR/Cas9***构建Atp7b基因敲除小鼠模型方法简单易行,周期短,拿到阳性小鼠的概率高,利用该小鼠模型可以充分研究该疾病的致病机理,并为进一步开发针对该疾病的治疗方式提供服务。
以上仅为本发明的较佳实施例而已,不能以此限定本发明的保护范围,即大凡依本发明权利要求书及发明内容所做的简单的等效变化与修改,皆仍属于本发明专利申请的保护范围。
SEQUENCE LISTING
<110> 赛业(苏州)生物科技有限公司
<120> 靶向小鼠Atp7b基因的gRNA及构建Wilson 疾病小鼠模型的方法
<130> 2021
<160> 7
<170> PatentIn version 3.5
<210> 1
<211> 23
<212> DNA
<213> 人工
<400> 1
ggcacccagg ccaaatgtag ggg 23
<210> 2
<211> 23
<212> DNA
<213> 人工
<400> 2
gactcttacc actgctaagt ggg 23
<210> 3
<211> 23
<212> DNA
<213> 人工
<400> 3
tctttgctaa ggagtaaaac tgg 23
<210> 4
<211> 23
<212> DNA
<213> 人工
<400> 4
gtggaagaga ggagatggta aac 23
<210> 5
<211> 23
<212> DNA
<213> 人工
<400> 5
gtggaagaga ggagatggta aac 23
<210> 6
<211> 25
<212> DNA
<213> 人工
<400> 6
catggttcaa gttcacatag tccag 25
<210> 7
<211> 23
<212> DNA
<213> 人工
<400> 7
tcagctcaag tggtaagtcc tgg 23
Claims (10)
1.一组靶向小鼠Atp7b基因的gRNA,其特征在于,包括三条gRNA,其核酸序列分别为:
gRNA1=SEQ ID NO 1=5’ -GGCACCCAGGCCAAATGTAGGGG-3’;
gRNA2=SEQ ID NO 2=5’ -GACTCTTACCACTGCTAAGTGGG-3’;
gRNA3=SEQ ID NO 3=5’ -TCTTTGCTAAGGAGTAAAACTGG-3’。
2.一种靶向小鼠Atp7b基因的基因敲除试剂盒,其特征在于,所述试剂盒中包括如权利要求1中的一组靶向小鼠Atp7b基因的gRNA。
3.使用如权利要求1所述的一组靶向小鼠BBS5基因的gRNA构建Wilson 疾病小鼠模型的方法,其特征在于,所述方法包括利用gRNA1、gRNA2、gRNA3将小鼠Atp7b基因敲除。
4.根据权利要求3所述的方法,其特征在于,所述gRNA1靶向切割小鼠Atp7b基因Exon2的5’端,gRNA2和gRNA3靶向切割Exon20的3’端。
5.根据权利要求4所述的方法,其特征在于,所述gRNA1、gRNA2、gRNA3将Atp7b基因第2~第20个外显子之间的33183bp的DNA切除。
6.根据权利要求3所述的方法,其特征在于,包括以下步骤:
1)将Cas9 mRNA以及针对Atp7b基因合成的3条gRNA混合后注射到培养于M2培养基中具有双核清晰的受精卵的细胞核中;
2)注射后的受精卵培养在特定的培养基中,培养至3.5天后每15-20个囊胚移植到假孕母鼠体内,产出小鼠,即为F0小鼠;
3)仔鼠出生后5天即可剪鼠尾提取DNA进行PCR扩增鉴定并送测序,若有检测结果为阳性则表示小鼠基因敲除成功。
7.根据权利要求6所述的方法,其特征在于,所述步骤3中的测序引物为:
PCR测序引物=SEQ ID NO 4=5’- GTGGAAGAGAGGAGATGGTAAAC -3’。
8.根据权利要求6所述的方法,其特征在于,所述步骤3中PCR鉴定中的引物包括:
PCR Primers1,其序列分别为:
F1=SEQ ID NO 5=5’- GTGGAAGAGAGGAGATGGTAAAC -3’;
R1= SEQ ID NO 6=5’- CATGGTTCAAGTTCACATAGTCCAG -3’。
9.根据权利要求6所述的方法,其特征在于,所述步骤3中PCR鉴定中的引物包括:
PCR Primers2,其序列分别为:
F2=SEQ ID NO 7=5’- TCAGCTCAAGTGGTAAGTCCTGG -3’;
R1=SEQ ID NO 6=5’- CATGGTTCAAGTTCACATAGTCCAG -3’。
10.如权利要求3-9任一项所述的方法构建获得的Wilson 疾病模型小鼠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111106595.5A CN113736787A (zh) | 2021-09-22 | 2021-09-22 | 靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111106595.5A CN113736787A (zh) | 2021-09-22 | 2021-09-22 | 靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113736787A true CN113736787A (zh) | 2021-12-03 |
Family
ID=78740197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111106595.5A Pending CN113736787A (zh) | 2021-09-22 | 2021-09-22 | 靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113736787A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114958923A (zh) * | 2022-06-28 | 2022-08-30 | 赛业(苏州)生物科技有限公司 | 一种Nr1d1基因敲除小鼠动物模型的构建方法及其应用 |
CN114958917A (zh) * | 2022-06-21 | 2022-08-30 | 赛业(苏州)生物科技有限公司 | 一种克罗恩病小鼠动物模型的构建方法和应用 |
CN115197962A (zh) * | 2022-07-07 | 2022-10-18 | 赛业(苏州)生物科技有限公司 | 一种Sirt3基因敲除小鼠动物模型的构建方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112553254A (zh) * | 2020-12-23 | 2021-03-26 | 成都药康生物科技有限公司 | 一种il10基因敲除小鼠模型及其构建方法、应用 |
CN112662669A (zh) * | 2020-12-23 | 2021-04-16 | 成都药康生物科技有限公司 | 一种Il21基因敲除小鼠模型及其构建方法、应用 |
-
2021
- 2021-09-22 CN CN202111106595.5A patent/CN113736787A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112553254A (zh) * | 2020-12-23 | 2021-03-26 | 成都药康生物科技有限公司 | 一种il10基因敲除小鼠模型及其构建方法、应用 |
CN112662669A (zh) * | 2020-12-23 | 2021-04-16 | 成都药康生物科技有限公司 | 一种Il21基因敲除小鼠模型及其构建方法、应用 |
Non-Patent Citations (3)
Title |
---|
XIAOXIAO MI等: "Activation of HIF-1 signaling ameliorates liver steatosis in zebrafish atp7b deficiency (Wilson\'s disease) models", 《BBA - MOLECULAR BASIS OF DISEASE》, pages 1 - 14 * |
董健健: "应用CRISPR/Cas9技术构建Wilson病小鼠模型及其基因治疗研究", 《中国博士学位论文全文数据库 医药卫生科技辑》, pages 060 - 22 * |
赵雯等: "Wilson病的动物模型研究进展", 《安徽医学》, vol. 35, no. 11, pages 139 - 142 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114958917A (zh) * | 2022-06-21 | 2022-08-30 | 赛业(苏州)生物科技有限公司 | 一种克罗恩病小鼠动物模型的构建方法和应用 |
CN114958923A (zh) * | 2022-06-28 | 2022-08-30 | 赛业(苏州)生物科技有限公司 | 一种Nr1d1基因敲除小鼠动物模型的构建方法及其应用 |
CN115197962A (zh) * | 2022-07-07 | 2022-10-18 | 赛业(苏州)生物科技有限公司 | 一种Sirt3基因敲除小鼠动物模型的构建方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106047930B (zh) | 一种PS1基因条件性敲除flox大鼠的制备方法 | |
CN107475300B (zh) | Ifit3-eKO1基因敲除小鼠动物模型的构建方法和应用 | |
CN110551759B (zh) | 一种提高转基因细胞重组效率的组合物及方法 | |
CN113736787A (zh) | 靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 | |
WO2018177351A1 (zh) | 基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法 | |
CN110904103A (zh) | 一种GRNa基因敲除斑马鱼突变体及其制备方法 | |
CN106282231B (zh) | 粘多糖贮积症ii型动物模型的构建方法及应用 | |
CN113755498A (zh) | 靶向小鼠Ube3a基因的gRNA及构建AS疾病小鼠模型的方法 | |
CN107119076A (zh) | 一种免疫缺陷小鼠模型、其制备方法及应用 | |
CN108753834B (zh) | ddx27基因缺失斑马鱼突变体的制备方法 | |
WO2022148078A1 (zh) | 对动物受精卵进行电转染基因编辑的方法及其应用 | |
Kang et al. | Apancreatic pigs cloned using Pdx1-disrupted fibroblasts created via TALEN-mediated mutagenesis | |
WO2021057806A1 (zh) | 糖尿病疾病模型犬的建立方法 | |
CN113234756A (zh) | 一种基于CRISPR/Cas9技术的LAMA3基因敲除动物模型的构建方法 | |
CN116083482A (zh) | B细胞条件性敲除dhx9基因小鼠模型的构建方法 | |
CN113564204B (zh) | 细胞色素p450酶人源化大鼠模型及其构建方法和应用 | |
CN112680479A (zh) | Cyp1b1基因缺失斑马鱼的制备 | |
CN112695034A (zh) | ApoE基因缺失斑马鱼的制备 | |
CN113249409A (zh) | 一种bmi1基因缺失斑马鱼 | |
CN111972355A (zh) | GSDIa型糖原累积症小鼠模型及其构建方法 | |
CN115807035B (zh) | 一种基于CRISPR/Cas9构建TLR2基因敲除小鼠动物模型的方法及其应用 | |
CN114592011B (zh) | 一种ptdss2条件性基因敲除小鼠模型的构建方法 | |
WO2019040744A1 (en) | METHODS AND COMPOSITIONS FOR IN SITU GERMINAL GENOMIC GENE ENGINEERING | |
CN114958917A (zh) | 一种克罗恩病小鼠动物模型的构建方法和应用 | |
CN112813106A (zh) | Ldlr基因缺失斑马鱼的制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211203 |